18F-grazy-02 PET/CT of Granzyme B Expression for Monitoring Immunotherapy
ConditionCancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorPeking University Cancer Hospital & Institute
About this trial
This is an open-label PET/CT study to investigate the safety and clinical monitoring value of 18F-grazy-02 in patients with lymphoma or solid tumors receiving immunotherapy, including immune checkpoint inhibition and CAR-T cell therapy.
Eligibility criteria
Qualifiers
18-75 years old;
ECOG score 0 or 1 point;
Participants with suspected or confirmed non-small cell lung cancer or melanoma who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.
Disqualifiers
Pregnant or nursing;
Severe hepatic or renal dysfunction;
Low WBC (less than 3 x 10^9/L);
Unable to comply with the PET/CT imaging procedures.
Trial design
Treatments tested in this trial
- 18F-grazy-02
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov